polatuzumab vedotin,axicabtagene ciloleucel,lisocabtagene maraleucel
gilead,roche,bms,daiichi sankyo
['zuma-7', 'transform,(-transformi),(-transforme),(-transforma),(-transforms),(-transform1),(-transform 1),(-transform-1),(-transform2),(-transform 2),(-transform-2)', 'lymsm', ' pola ', 'dlbcl']
congress | #ash22
alex f. herrera discusssed the safety and efficacy of polar-ice as a 2nd line therapy for pts with r/r dlbcl. 39 % of pts proceeded to pola consolidation. after 2 cycles, the orr was 88%, with a similar safety profile to rice. med follow up is 6.6mo.
#lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm